234 results about "E coli bacteria" patented technology

Escherichia coli is modified by means of metabolic engineering, a genetically engineered bacterium for high yield of O-succinyl-L-homoserine is obtained, and a construction method of the genetically engineered bacterium comprises the following steps: weakening a synthetic route of an organic acid metabolic byproduct of a chassis strain E.coli W3110 [delta] metI [delta] metJ [delta] thrB [delta] metB; wherein the synthetic route of the organic acid metabolic byproducts is selected from at least one of a formic acid synthetic route, a lactic acid synthetic route and an ethanol synthetic route. The constructed genetically engineered bacterium is applied to microbial fermentation production of the O-succinyl-L-homoserine, effective accumulation of the O-succinyl-L-homoserine is achieved, the sugar acid conversion rate reaches 46.8%, and a foundation is laid for subsequent construction of high-yield O-succinyl-L-homoserine engineering bacteria.

The invention belongs to the field of metabolic engineering, and discloses a genetically engineered bacterium for producing myo-inositol as well as a construction method and application of the genetically engineered bacterium. The genetically engineered bacterium takes escherichia coli as an original strain, and is obtained by performing the following gene editing on a genome of the escherichia coli: non-expressed lactose operon repressor protein, glucose phosphate dehydrogenase, acetokinase, glucose phosphate isomerase and glycerol repressor protein; and overexpressing inositol-1-phosphate synthase, inositol monophosphate, glucokinase, glucose permease and glycerol kinase. Compared with the prior art, the genetically engineered bacterium disclosed by the invention has remarkable advantages in the aspects of key enzyme expression rate, metabolism specificity, fermentation period and the like, and an efficient, stable, economical and feasible solution is provided for industrial production of myo-inositol.

The invention discloses a preparation method and application of a cat main allergen FEL-1 nano antibody FEL-1-Nb, and relates to the technical field of antibody preparation, and the preparation method comprises the following steps: preparing an immunogen; animal immunization and library construction; constructing and panning a phage display library; screening and identifying positive clone; and expression and purification of the nano antibody: cloning the positively cloned VHH gene to an expression vector such as a pET series, transforming an expression strain such as escherichia coli BL21 (DE3), carrying out IPTG induced expression, and purifying through an inclusion body purification method to obtain a high-purity nano antibody protein. The nano antibody FEL-1-Nb provided by the invention can be specifically bound with a cat main allergen FEL-1 protein, the unique amino acid sequence of the nano antibody FEL-1-Nb is shown as SEQIDNO: 1, high-affinity binding with the FEL-1 protein is ensured, the positive clone binding rate is high through phage display panning and ELISA verification, the phage recovery rate after the third round of panning is increased by more than 1000 times compared with the first round of panning, and the positive clone binding rate is higher than that of the first round of panning. Therefore, the nano antibody has excellent targeted recognition capability.

The present invention relates to the use of a combination of a saccharide and glycerol for skin protection against undesirable bacteria. The present invention is particularly useful in the formulation of compositions that act as prebiotics for commensal skin bacteria such as S. epidermidis to produce metabolites such as lactic acid, which, through the present invention, has been shown to inhibit the growth of undesirable bacteria such as E. coli and S. aureus, among others. The present invention is especially useful because it provides both short-term (i.e., rapid) and long-term (or sustained) protection.

The invention discloses a recombinant bacterium capable of increasing the yield of alpha-bisabolol as well as a preparation method and application of the recombinant bacterium, and belongs to the technical field of microorganisms. The invention aims to improve the yield of alpha-bisabolol and enhance the tolerance of a host to an organic solvent. The invention provides a recombinant bacterium for improving the yield of alpha-bisabolol. Escherichia coli is used as a starting strain; the method comprises the following steps of: overexpressing an acetyl CoA acyltransferase / HMG-CoA reductase mvaE gene, an HMG-CoA synthetase mvaS gene, a 2-methyl citrate dehydratase prpD gene, a mevalonate kinase ERG12 gene, a mevalonate 5-phosphate kinase ERG8 gene, a mevalonate 5-diphosphate decarboxylase ERG19 gene and an isopentenyl diphosphate isomerase idi gene, so as to obtain a recombinant vector; the gene is obtained from an alpha-bisabolol synthase gene of artichoke, a farnesyl diphosphate synthase ispA gene and an alpha-bisabolol synthase CcBOS gene of artichoke. The industrial process of synthesizing alpha-bisabolol by a biological method is promoted.

The invention relates to the technical field of bioengineering, in particular to a preparation method and application of an antibacterial peptide, and the amino acid sequence of the antibacterial peptide is shown as SEQ ID No: 1 and is named as L8. The preparation method of the antibacterial peptide L8 comprises the following steps: S1, obtaining an L8 target gene segment; connecting an L8 target gene segment with a pLC vector to obtain a connection product; transforming the connection product into an escherichia coli DH5-alpha competent cell, and screening positive clones to obtain a pLC-L8 recombinant plasmid; s2, taking the pLC-L8 recombinant plasmid as a substrate, and carrying out cell-free protein synthesis reaction to obtain the antibacterial peptide L8, the cell-free protein synthesis system comprises 175 mM of potassium glutamate, 10 mM of ammonium glutamate, 2.7 mM of potassium oxalate, 33 mM of PEP, 38 mM of compound amino acid, 10 mM of magnesium glutamate, 2% (w / v) PEG-8000, 5 nM of pLC-L8 recombinant plasmid, 11.25 mM of lactose, 33.33% (v / v) of crude extract, 100 mg / mL of escherichia coli tRNA and 2.5 nM of T7 RNA polymerase. The antibacterial peptide L8 is obtained by optimizing the antibacterial peptide LRGG, and compared with the LRGG, the antibacterial peptide L8 subjected to cell-free protein synthesis reaction expression has better antibacterial activity and biological safety.

The invention discloses a conservative B cell epitope peptide of goose parvovirus VP3 protein, a nucleic acid molecule, a recombinant vector and application thereof. Conservative B cell epitope EW12 is inserted into F18 Escherichia coli Fod fimbriae, inert carrier bacteria S9H are introduced, recombinant bacteria capable of functionally exhibiting and expressing the EW12 conservative B cell epitope on the surface of the bacteria are obtained, the recombinant bacteria can specifically generate specific binding reaction with gosling plague egg yolk antibody and gosling plague vaccine immune serum, and the gosling plague egg yolk antibody and the gosling plague vaccine immune serum can be specifically combined with the gosling plague egg yolk antibody and the gosling plague vaccine immune serum. The method has the advantages that macroscopic agglutination particles are generated, cross agglutination reaction with other pathogen positive serum and healthy goose serum is avoided, the method is good in sensitivity, and the specific antibody can be detected in the 5th day after immunization at the earliest. A plate agglutination test directly mediated by the goose parvovirus VP3 protein conservative B cell epitope peptide EW12 has the advantages of specificity, sensitivity, convenience in operation and suitability for on-site large-scale rapid detection, and is expected to provide a new technical means for diagnosis, prevention and control and purification of GPV infection.

The present application relates to the technical field of fermentation engineering, and provides an engineered Escherichia coli for producing uroporphyrin as well as a construction method and application thereof.The present application uses Escherichia coli to express porphyrin synthase of thermophilic bacteria, performs whole-cell catalysis of 5-ALA to synthesize uroporphyrin under high-temperature conditions, and completely shields endogenous regulation; further, the Escherichia coli is wrapped by COF material to prevent the loss of enzymes in the cell recovery process; and a protein scaffold based on dockerin-cohesin is constructed to further improve the yield of uroporphyrin III.The present application creates a brand-new uroporphyrin high-temperature whole-cell catalysis process, realizes the efficient production of uroporphyrin, and provides a basis and idea for the industrial production of uroporphyrin.

The invention discloses a protein sequence analysis method, equipment, a medium and a product, and relates to the technical field of combination of biotechnology and artificial intelligence. The method comprises the steps that a first protein sequence is obtained, corresponding first embedding expression is constructed, and the first protein sequence is an exogenous protein sequence which is expressed in Escherichia coli or is to be expressed in Escherichia coli and is not from Escherichia coli; inputting the first embedded representation into a pre-trained proteotoxicity analysis model to obtain a prediction result aiming at whether the first protein sequence is toxic to escherichia coli or not; the model is a convolutional neural network model based on a channel attention mechanism and a space attention mechanism. According to the technical scheme provided by the embodiment of the invention, the problem that a method for analyzing the toxicity of the escherichia coli by aiming at the protein sequence cannot give consideration to both efficiency and accuracy is solved, and the toxicity of the endogenous or exogenous protein sequence expressed in the escherichia coli to the escherichia coli can be efficiently, stably and accurately predicted and analyzed.

The invention discloses a method for catalytically synthesizing adenosine triphosphate by using microcrystalline cellulose carrier purification immobilized enzyme, which comprises the following steps: preparing bacterial suspension by using escherichia coli wet thalli and Tris-HCL buffer solution, crushing, centrifuging, and taking supernate to obtain crude enzyme; adding a microcrystalline cellulose carrier and the wet thalli into the crude enzyme liquid, and washing the immobilized enzyme after immobilization to obtain the immobilized enzyme; the method comprises the following steps: adding immobilized enzyme adenosine kinase and immobilized polyphosphate kinase into a substrate system with the volume of 1L according to a weight ratio, and starting a catalytic reaction under the conditions that the pH is 5.5-7.5 and the temperature is 20-40 DEG C; after catalysis is finished, the immobilized enzyme adenosine kinase and the immobilized polyphosphate kinase are subjected to solid-liquid separation with reaction liquid through a Buchner funnel, the immobilized enzyme continues to be subjected to catalytic reaction, and the method for preparing the immobilized enzyme is simple in mode, low in cost, easy to industrially produce, high in stability and capable of being repeatedly used for many times, and products are easy to separate.

A vaccine comprising effective amounts of i) E. coli colonization factor antigens comprising CFA / I, CS3, CS5 and CS6 antigens; ii) a heat labile enterotoxin B subunit antigen being an LCTBA protein; and iii) an adjuvant being double mutant (R192G / L211A) of E. coli heat-labile toxin (dmLT), for use in inducing protective immunity against diarrheal disease caused by Salmonella spp. and / or Shigella spp.

This invention discloses a recombinant vector, recombinant bacteria, and fermentation method for high-yield GHK production, belonging to the field of biomedical technology. The recombinant expression vector of this application comprises a bicistronic expression cassette controlled by a T7 / lac heterozygous promoter, sequentially containing the encoding (GHK). n The vector encodes the first cistron of the polypeptide and the second cistron, where n is an integer from 2 to 200. When this vector is transformed into *E. coli* BL21, the resulting recombinant bacteria can simultaneously express (GHK) after IPTG induction. n Polypeptides and trypsinogen. During fermentation, trypsinogen is activated and enables the processing of (GHK). n In situ enzymatic cleavage of peptides efficiently releases GHK. This invention integrates the traditional multi-step process into a "one-step fermentation," simplifying the production process and reducing purification difficulty. Examples show that the GHK yield can reach up to 3.9 g / L, providing an efficient and convenient new strategy for the large-scale biomanufacturing of GHK.

The application discloses a method for producing deoxythymidine triphosphate by using a recombinant strain, and comprises the following steps: step 1: using a CRISPR / Cas9-mediated gene editing method to perform targeted modification on an E. coli genome, and the targeted modification comprises the following contents: a. knocking out a nucleoside triphosphate pyrophosphatase gene (mazG / yhdE) to block a path of degrading dTTP into dTMP; b. knocking out a nucleotide nucleosidase gene (ppnN) to block a path of degrading dTMP into thymine; and c. knocking out a nucleotidase gene (yfbR / yfdR / ushA / umpH / umpG / yjjG) to block a path of degrading dTMP into dT. The application provides a method for producing deoxythymidine triphosphate by using a recombinant strain, and the conversion rate of the method reaches 80% to 90%, and after ion exchange chromatography purification, the purity can reach more than 99%.

The invention provides a composition comprising a Plasmodium species multimeric protein capable of forming a nanoparticle and at least one antigen of interest, wherein the multimeric protein comprises a monomer chosen from Plasmodium species pyridoxal 5'-phosphate synthase (PLP), chaperone 60 protein (Cpn60), and caseinolytic protease (Clp). In embodiments, the invention provides the composition wherein the monomers assemble to form a multimeric nanoparticle and / or which comprises an adjuvant. The invention further provides a nucleic acid encoding the multimeric protein and the at least one antigen of interest, E. coli comprising the nucleic acid, and the use of such in a method for producing the inventive multimeric protein and the at least one antigen of interest. Also provided are a method and use of the inventive multimeric protein and the at least one antigen of interest for immunizing a subject against Plasmodium species.

The invention discloses a recombinant full-length human-derived III-type collagen as well as a preparation method and application of the recombinant full-length human-derived III-type collagen. The method comprises the following steps: replacing at least one corresponding rare codon of glycine, proline, arginine, leucine, isoleucine, valine and / or glutamic acid host bacteria in a Gly-Pro-X or Gly-X-Pro tripeptide structure coded by a wild full-length human III-type collagen gene sequence with a synonymous codon used by the host bacteria at high frequency; the translation efficiency in prokaryotic systems such as escherichia coli is obviously improved; the method comprises the following steps: designing 6-12 gene segments with overlapping sequences, splicing by adopting an overlapping extension PCR (Polymerase Chain Reaction) technology to obtain a full-length optimized gene, constructing the full-length optimized gene to an expression vector, and transforming the full-length optimized gene into host bacteria for induced expression; the expression product exists in the form of an inclusion body, and the natural conformation of the expression product is recovered through in-vitro renaturation; according to the method, high-efficiency expression and active preparation of the full-length human-derived III-type collagen in a prokaryotic system are realized.

This invention discloses a method for preparing and applying plant sulfonated small peptide PSK based on synthetic biology, belonging to the field of biotechnology. Based on the design concept of synthetic biology, this invention constructs an orthogonal synthetic system composed of genetic code expansion technology and SUMO fusion protease digestion technology. A specific PSK dotted vector and a pUltra-sY vector are co-transformed into *E. coli* to construct a genetically engineered strain. The sulfonated small peptide PSK precursor is expressed in this genetically engineered strain, and mature plant sulfonated small peptide PSK is obtained through specific hydrolysis by SUMO protease. This method significantly improves the synthesis efficiency and purity of sulfonated small peptides and has broad application prospects in agricultural production and biotechnology.

The invention discloses bacillus subtilis for recombinant expression of a hermetia illucens HIAMP0438 gene and a construction method of the bacillus subtilis, and belongs to the technical field of gene engineering. The hermetia illucens recombinant protein used in the invention is obtained by expression of bacillus subtilis WB800N transferred into a pHT43-HIAMP0438 high-efficiency expression vector, and the pHT43-HIAMP0438 high-efficiency expression vector is obtained by a homologous recombination technology, so that high-level expression of the HIAMP0438 gene is realized, the HIAMP0438 gene can be efficiently secreted out of cells, the preparation process of the recombinant protein is greatly simplified, and the production cost is reduced. According to the present invention, the recombinant protein can significantly inhibit the growth of Escherichia coli, Salmonella and Listeria monocytogenes, and the recombinant protein can be used as the animal health product, and can be used for preventing and treating pig and chicken intestinal diarrhea caused by Escherichia coli and Salmonella and food-borne digestive tract diseases caused by Listeria monocytogenes.

The invention provides a method for synthesizing melanin nanoparticles by using escherichia coli, and belongs to the technical field of biological genetic engineering. According to the method, a bacillus megaterium-derived tyrosinase gene Tyr1 (SEQ ID NO.2) after codon optimization is taken as a target gene, a recombinant expression plasmid pET-24a-Tyr1 is constructed, and the recombinant expression plasmid pET-24a-Tyr1 is transformed into an escherichia coli BL21 (DE3) competent cell to obtain the genetically engineered bacterium. After the engineering bacterium induces expression of tyrosinase through IPTG (isopropyl-beta-d-thiogalactoside), polymerization of an L-tyrosine substrate is catalyzed in the presence of CuSO4 to obtain high-purity melanin nanoparticles. The melanin nano-particles synthesized by the method are uniform in particle size, have wide-spectrum strong absorption characteristics in a wavelength range of 400-800nm, show excellent photo-thermal performance, free radical scavenging capacity and biocompatibility, and have wide application prospects in the fields of biomedicine and functional materials.

Antimicrobial eyewear features frames infused with or coated with antimicrobial additives, thereby offering continuous protection by actively destroying and inhibiting the growth of bacteria, fungi, parasites, and some viruses. The lenses may also have an antibacterial coating that destroys and inhibits bacterial growth. In some examples, the lenses are treated with a specialized strengthening liquid, wherein the liquid contains nano components that release heavy metal ions capable of invading the cell walls of bacteria, leading to bacterial elimination, destroying DNA molecules and proteases within the bacterial cells, denature viral proteins, break DNA chains, and result in cell death. Additionally, the strengthening liquid reduces dehydrogenase activity and interacts with various protein groups within the cell, thereby reducing the activity of these groups and effectively inhibiting the growth of E. coli and other bacteria on the lens surface.

The present disclosure relates to the field of biotechnology, and in particular to method for modifying a high-yield L-lysine-producing strain engineering and application thereof. The present disclosure provides a recombinant strain obtained by knocking out the cbrB gene and / or the cbrC gene in the genome of E. coli. Fermentation of the recombinant strain can increase the yield and conversion rate of L-lysine and reduce the mortality rate of the strain during the fermentation process. The present disclosure has significant application value. Through experimental studies, it was found that these two genes have a synergistic effect on E. coli. L-lysine hydrochloride imposes osmotic stress resistance on the strains, and silencing the related gene proteins can alter the membrane lipid composition (increasing a proportion of unsaturated fatty acids), maintain membrane fluidity, improve tolerance to lysine hydrochloride, and reduce the mortality rate in the late stage of fermentation.

The invention provides an acoustic-magnetic dual-mode diagnosis and treatment agent as well as a preparation method and application thereof, and belongs to the technical field of preparation of tumor diagnosis and treatment agents. The acoustic-magnetic dual-mode diagnosis and treatment agent is surface-modified magnetic nanoparticles which contain nano balloon genes and are subjected to Escherichia coli induced expression; the nucleotide sequence of the nano-balloon gene is a sequence shown as NCBI: KC601845.1, escherichia coli in the acoustic-magnetic dual-mode diagnosis and treatment agent as a diagnosis and treatment agent carrier has an active targeting property on a tumor hypoxic region, and bacteria contain a nano-balloon and have an acoustic response characteristic; the escherichia coli surface modified magnetic nanoparticles have a magnetic response characteristic. In acoustic-magnetic dual-mode imaging, firstly, on a real-time ultrasonic contrast monitoring image, a nano air bag expressed in bacteria can generate an enhanced tumor ultrasonic echo signal; secondly, under the action of an external changing magnetic field, the magnetic nanoparticles on the surfaces of the bacteria can generate an enhanced tumor magnetic vibration imaging effect, so that more efficient tumor diagnosis and / or treatment can be realized.

This invention belongs to the field of biotechnology, specifically relating to a method for promoting the soluble expression of TAFA4 and its applications. The invention involves inserting a nucleic acid fragment containing the TAFA4 encoding gene into a pET32a vector with a Trx tag; transforming *E. coli* to express the Trx-TAFA4 fusion protein; and obtaining the Trx-TAFA4 fusion protein through IPTG induction and purification. The preparation method provided by this invention is low-cost, short-cycle, easy for large-scale high-density culture, and has low risk, resulting in stable protein yield and quality. The Trx-TAFA4 fusion protein obtained through the above preparation method has immunomodulatory effects and can be used for drug development and subsequent research.

The invention discloses a method for drawing a human full-coverage protein interaction network based on digital PCR next-generation sequencing. After the advanced pedestrian 293T cell line obtains mRNA, a modified random primer or an oligo-dT primer is adopted to obtain a cDNA library; carrying out homogenization treatment on the human cDNA library; the method comprises the following steps: transforming plasmids of a BACTH bacteria double-hybrid system to obtain transformed plasmids; carrying out homologous recombination on the transformed plasmids of the sample library and the double-impurity system, and introducing into escherichia coli for screening to obtain positive PPI clones of the library with interaction; and carrying out digital PCR-based next-generation sequencing on the screened clones to draw the human full-coverage protein interaction network. The method is suitable for performing high-throughput screening after thousands of positive PPI combinatorial clones are obtained by'library-to-library 'bacteria or yeast double hybrids, identifying the same cell bar code cDNA combinatorial pairs, and realizing PPI network identification in different species, among species and in hybridization technology system extensive scenes.

The invention belongs to the technical field of gene intervention, and provides a feeding-mediated marine mussel gene silencing method which comprises the following steps: linearizing plasmids to obtain linearized plasmids; determining a cDNA fragment of the target gene from the target mussel, and performing amplification by using the specific primer pair to obtain a target gene fragment; connecting the target gene segment with the linearized plasmid to obtain a connection product; transforming the connection product into escherichia coli, screening to obtain a positive strain, extracting target recombinant plasmids, and transforming the target recombinant plasmids into escherichia coli for expressing dsRNA to obtain engineering bacteria; engineering bacteria and microalgae are mixed according to the cell number ratio of (90-110): (1-2), a bacteria-algae feeding mixture is obtained, and mussels are fed with artificial seawater containing the bacteria-algae feeding mixture for 1-10 d. The method disclosed by the invention does not cause antioxidant system disorder or energy metabolism abnormality, and is a gene silencing strategy with higher biological safety.

The invention discloses a biosynthesis method of nylon salt, and belongs to the field of bioengineering. According to the arginine decarboxylase mutant AdiAT204E / H736E, the arginine decarboxylase mutant AdiAT204E / H736E which is most suitable for up-regulation of pH is obtained. The mutant AdiAT204E / H736E keeps relatively high activity in the whole neutral and alkaline range of pH (Potential of Hydrogen) of 7.0 to 9.0. Further, the mutant AdiAT204E / H736E is expressed in escherichia coli, a genetically engineered bacterium with butanediamine yield reaching 138 g / L is constructed, arginine regulated by adipic acid is further used as a substrate, butanediamine is generated under the action of the genetically engineered bacterium, butanediamine and adipate ions are further heated to react, and the butanediamine with adipate ions is obtained. And nylon salt is directly extracted and purified from the reaction liquid.

The invention belongs to the technical field of genetic engineering, and discloses application of an anchoring protein INP-N in a PET degrading enzyme system displayed on the surface. According to the invention, after efficient anchoring protein INP-N is screened, FAST-PETase is mediated by the efficient anchoring protein INP-N to construct recombinant escherichia coli of which the surface displays PET degrading enzyme. Furthermore, hydrophobin HFBII is introduced into the surface display system, so that the relative enzyme activity of the PET degrading enzyme is improved by 1.1 times or more. Meanwhile, FAST-PETase and carboxylesterase Est30KL are synchronously expressed, so that the proportion of TPA in a degradation product can reach 95% or above. In addition, the PET degrading enzyme surface display system provided by the invention is excellent in cycle performance, more than 65% of activity can still be retained when PET is cyclically degraded for the third time, and the application cost can be greatly reduced. The method can be applied to the fields of degradation of PET products, preparation of PET degradation agents or BHET degradation agents and the like.

The invention relates to the technical field of molecular biology and immunity, in particular to urechis unicinctus C-type lectin and a preparation method and application thereof. The amino acid sequence of the urechis unicinctus C-type lectin is as shown in SEQ ID No. 1. The C-type lectin is a recombinant protein obtained by expression in escherichia coli. The recombinant protein can be widely combined and agglutinated with various gram-positive bacteria and gram-negative bacteria, and can promote the removal of pathogenic bacteria in urechis unicinctus. The recombinant C-type lectin can be used for preparing a bacterial agglutination preparation, an anti-bacterial infection preparation and the like, and is especially suitable for prevention and control of aquaculture pathogenic bacteria.

The invention relates to aminoacyl-tRNA synthetases that aminoacylate tRNA with 2-Aminoisobutyric acid (Aib), thus enabling the incorporation of the Aib into a growing polypeptide chain during translation, e.g. in eubacterial host cells such as E. coli. For example, but not limited to, the invention relates to new aminoacyl-tRNA synthetases and the uses hereof, as well as a method for producing polypeptides that contain one or more Aib.

The application discloses a preparation method of E. coli extracellular vesicles and application of the E. coli extracellular vesicles in anti-breast cancer drugs. The preparation method of the E. coli extracellular vesicles comprises the following steps: knocking out a 3-dehydroquininase gene of E. coli to obtain a recombinant bacterium; lysing the recombinant bacterium and performing low-speed centrifugation to obtain a supernatant and a lysate; performing high-speed centrifugation on the lysate to obtain a precipitate, which is the E. coli extracellular vesicles. The E. coli extracellular vesicles prepared by the method can be applied to the preparation of anti-tumor drugs. The 3-dehydroquininase (aroD) gene of E. coli is singly knocked out to construct a recombinant bacterium strain, and OMVs extracted from the strain can directly inhibit the proliferation of HER2-negative Luminal A type breast cancer and triple-negative breast cancer, but the inhibiting effect on the proliferation of other subtypes of breast cancer is poor. The OMVs prepared by the application can provide a new path for the design and screening of anti-tumor drugs, and have a good drug-making prospect.

The invention relates to the technical field of microbial fermentation, and discloses bacillus subtilis, application of the bacillus subtilis in fermented soybean meal and a preparation method of the fermented soybean meal. The bacillus subtilis screened by the invention has strong anti-nutritional factor resistance (such as glycinin, beta-conglycinin, raffinose and stachyose), has a good growth effect in the soybean meal raw material, and is used for fermenting the soybean meal raw material; the content of anti-nutritional factors (such as glycinin, beta-conglycinin, raffinose and stachyose) in the soybean meal raw material can be obviously reduced, and meanwhile, the content of lipopeptide substances (such as surfactin and bacitracin D) in the fermented soybean meal product can be obviously improved; the prepared fermented soybean meal product has a good antibacterial effect on three common intestinal pathogens (escherichia coli, salmonella and staphylococcus) in animal bodies.